Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: New England Biolabs, RareCyte, Congenica, More

New England Biolabs RUO SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit

New England Biolabs has launched a real-time loop-mediated isothermal amplifcation-based (RT-LAMP) assay kit to detect SARS-CoV-2. The research-use-only kit, called the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, enables visual amplification detection using a simple heat source, with results in 30 minutes. The kit includes the firm's WarmStart Colorimetric LAMP 2X Master Mix with uracil-DNA glycosylase, a primer mix targeting the N and E regions of the SARS-CoV-2 genome, an internal control primer set and positive control template, as well as guanidine hydrochloride to increase the speed and sensitivity of the RT-LAMP reaction.


RareCyte Orion Platform

RareCyte has launched a new spatial biology analysis platform called Orion. The system is based on a patented and proprietary microscopy technology that allows comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment at what the company claims are much faster speeds and with more efficiency than existing technologies.

The platform includes the Orion instrument and associated TissuePlex reagents. The instrument images an entire pathology slide at high speed and high resolution in 21 fluorescence channels. Companion TissuePlex panels are shipped as customizable catalog labelling kits. Customers can also access the technology through RareCyte laboratory services and other specified programs.


Congenica Automation

Congenica has updated its clinical decision support platform by launching the Automated Classification of Known Variants product, Congenica Automation. This will provide automated classification as well as evidence and reporting of recurrent 'known' variants that customers observe in their rare disease cases. The new product aims to reduce interpretation and reporting time by 90 percent compared to the company's existing solution, so complex genomic data can be reported in as little as 5 minutes. For example, interpretation and reporting of 4,000 cases with recurrent pathogenic or likely pathogenic variants could be completed in 5 to 8 minutes for each case. Users of the new product can also create their own customized curated variant list to be used for the automated process.


For more new products and services, please visit the New Products page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.